Compare · BSX vs CARL

BSX vs CARL

Side-by-side comparison of Boston Scientific Corporation (BSX) and Carlsmed Inc. (CARL): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both BSX and CARL operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
  • BSX is the larger of the two at $61.87B, about 143.7x CARL ($430.6M).
  • Over the past year, BSX is down 58.3% and CARL is up 15.5% - CARL leads by 73.9 points.
  • BSX has been more active in the news (10 items in the past 4 weeks vs 4 for CARL).
  • BSX has more recent analyst coverage (25 ratings vs 6 for CARL).
PerformanceBSX-58.34%CARL+15.52%
2025-10-31+0.00%2026-10-30
MetricBSXCARL
Company
Boston Scientific Corporation
Carlsmed Inc.
Price
$41.97-1.66%
$14.96-4.90%
Market cap
$61.87B
$430.6M
1M return
-2.96%
+8.52%
1Y return
-58.34%
+15.52%
Industry
Medical/Dental Instruments
Medical/Dental Instruments
Exchange
NYSE
NASDAQ
IPO
2025
News (4w)
10
4
Recent ratings
25
6
BSX

Boston Scientific Corporation

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.